Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.52 |
| ▸ | JAK2 | O60674 | 14/20 | 0.49 |
| ▸ | JAK1 | P23458 | 14/20 | 0.49 |
| ▸ | TYK2 | P29597 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893867 | 0.85 | SYK (0.51) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL10169191 | 0.81 | MAPK8 (0.54) | SYKNPC1MAPTAHRRAB9A | |
| SCHEMBL10169532 | 0.80 | JAK2 (0.49) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL10169198 | 0.80 | NPC1 (0.47) | SYKNPC1MAPTAHRRAB9A | |
| SCHEMBL893987 | 0.78 | LCK (0.53) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL29686385 | 0.78 | RAB9A (0.71) | SYKJAK2JAK1TYK2NPC1 | |
| SCHEMBL10169201 | 0.76 | SYK (0.51) | SYKNPC1MAPTAHRRAB9A | |
| SCHEMBL14808915 | 0.76 | JAK2 (0.49) | SYKJAK2JAK1TYK2 | |
| SCHEMBL10244483 | 0.75 | SYK (0.71) | SYK | |
| SCHEMBL10157957 | 0.74 | EML4 (0.50) | SYKJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | SYK 22/4885JAK2 123/4885JAK1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.